Advertisement

Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons

  • Chakrapani Balijepalli
  • Rohan Shirali
  • Prashanth Kandaswamy
  • Anastasia Ustyugova
  • Egon Pfarr
  • Søren S. Lund
  • Eric Druyts
Open Access
Correction
  • 104 Downloads

Correction to: Diabetes Ther (2018) 9:1491–1500  https://doi.org/10.1007/s13300-018-0456-7

In the original publication, Figure 3 was incorrectly published. The authors have updated figure 3 and the corrected Fig. 3 is given below.
Fig. 3

Plots presenting indirect comparisons of empagliflozin versus other glucose-lowering drugs

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Chakrapani Balijepalli
    • 1
  • Rohan Shirali
    • 1
  • Prashanth Kandaswamy
    • 2
  • Anastasia Ustyugova
    • 2
  • Egon Pfarr
    • 2
  • Søren S. Lund
    • 2
  • Eric Druyts
    • 1
  1. 1.Precision Health EconomicsVancouverCanada
  2. 2.Boehringer Ingelheim GmbHIngelheimGermany

Personalised recommendations